Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol
Pharmacology Biochemistry and Behavior · 2026-09 · 266 · 174220
DOI: 10.1016/j.pbb.2026.174220 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacology Biochemistry and Behavior, 2026-09. Verfasst von Pablo Sebastián Fortini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Equipo de Neurodesarrollo INIZIO, Santiago del Estero 321, Tucumán, Argentina. Electronic address: sebastianfortini@icloud.com. Hauptthemen laut MEDLINE: Cannabidiol, Autism Spectrum Disorder. Die Arbeit nennt 44 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition often associated with severe behavioral disturbances and limited pharmacological treatment options. Cannabidiol (CBD) has emerged as a potential therapeutic option; however, evidence on its long-term effectiveness and safety in children with ASD is scarce. OBJECTIVE: To evaluate the long-term effectiveness and safety of purified CBD as add-on therapy in children with severe ASD and treatment-resistant behavioral symptoms. MATERIAL AND METHODS: We conducted a prospective observational before-and-after study in children and adolescents (3-18 years) with ASD severity levels 2 or 3 and intellectual disability treated with add-on CBD. The primary outcome was change in caregiver-identified symptoms, while secondary outcomes included standardized behavioral scales (Repetitive Behavior Scale-Revised [RBS-R], Vineland Adaptive Behavior Scales-II maladaptive behavior domain, Aberrant Behavior Checklist [ABC], Pediatric Sleep Clinical Global Impressions-Severity, Autism Family Experience Questionnaire, and Parental Stress Scale). Safety and tolerability were assessed through caregiver-reported adverse events. RESULTS: Twenty children were enrolled, of whom 13 completed the long-term follow-up (mean 27.6 ± 1.3 months). Of the caregiver-identified symptoms, improvements observed during the initial short-term study were maintained or further improved during follow-up. Standardized scales showed modest but sustained improvements, particularly in irritability, social withdrawal, and hyperactivity. Mild, transient adverse events, mainly irritability or decreased appetite, did not recur during long-term followup, and concomitant medications were reduced in 40% of patients. CONCLUSION: Long-term treatment with purified CBD in children with severe ASD was well tolerated and associated with sustained improvement in caregiver-reported outcomes and standardized scales.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Equipo de Neurodesarrollo INIZIO, Santiago del Estero 321, Tucumán, Argentina. Electronic address: sebastianfortini@icloud.com.
- Hospital General de Agudos J.M. Ramos Mejía, Gral. Urquiza 609, 1221, Buenos Aires, Argentina. Electronic address: jtoibaro@gmail.com.
- Department of Neurology, Hospital de Pediatría Prof. Dr. J.P. Garrahan, Combate de los Pozos 1881, 1245, Buenos Aires, Argentina. Electronic address: robertohcaraballo@gmail.com.
Zitieren
APA
Fortini, P. S., Toibaro, J. J., & Caraballo, R. H. (2026). Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol. Pharmacology Biochemistry and Behavior, 266, 174220. https://doi.org/10.1016/j.pbb.2026.174220
Vancouver
Fortini PS, Toibaro JJ, Caraballo RH. Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol. Pharmacology Biochemistry and Behavior. 2026;266:174220. doi:10.1016/j.pbb.2026.174220
BibTeX
@article{Fortini2026,
author = {Fortini, Pablo Sebastián and Toibaro, Javier J and Caraballo, Roberto H},
title = {Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol},
journal = {Pharmacology Biochemistry and Behavior},
year = {2026},
volume = {266},
pages = {174220},
doi = {10.1016/j.pbb.2026.174220}
}
EUVIMED